Abstract
A novel, green, and atom-economical boric acid catalyzed direct amidation without the use of any coupling agents for the preparation of suberoylanilide hydroxamic acid (SAHA) and SAHA-based inhibitors targeting anti-proliferation of cancer cells is provided. The new SAHA-based inhibitor B123, when used alone, exhibited higher anti-proliferative activities than SAHA or Cisplatin against a number of human cancer cells. We have examined the effect of combination of these SAHA-based inhibitors with Cisplatin. We found synergistic effects of the combination of SAHA-based inhibitors with Cisplatin over a wide range of concentrations against human liver cancer cells HepG2 and two human lung cancer cell lines H1299 and H460. This synergism leads up to 8-fold of dose reduction for Cisplatin in the combination with our synthesized inhibitor B123 against H1299.
Keywords: Synergistic effect, anti-proliferation, SAHA-based inhibitors, Cisplatin, hydroxamic acids.
Medicinal Chemistry
Title:Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells
Volume: 12 Issue: 8
Author(s): Rui Xie, Jinghua Shi, Chunhui Cheng, Fan Yun, Xia Liu, Pingwah Tang, Xinying Wu, Ming Yang and Qipeng Yuan
Affiliation:
Keywords: Synergistic effect, anti-proliferation, SAHA-based inhibitors, Cisplatin, hydroxamic acids.
Abstract: A novel, green, and atom-economical boric acid catalyzed direct amidation without the use of any coupling agents for the preparation of suberoylanilide hydroxamic acid (SAHA) and SAHA-based inhibitors targeting anti-proliferation of cancer cells is provided. The new SAHA-based inhibitor B123, when used alone, exhibited higher anti-proliferative activities than SAHA or Cisplatin against a number of human cancer cells. We have examined the effect of combination of these SAHA-based inhibitors with Cisplatin. We found synergistic effects of the combination of SAHA-based inhibitors with Cisplatin over a wide range of concentrations against human liver cancer cells HepG2 and two human lung cancer cell lines H1299 and H460. This synergism leads up to 8-fold of dose reduction for Cisplatin in the combination with our synthesized inhibitor B123 against H1299.
Export Options
About this article
Cite this article as:
Xie Rui, Shi Jinghua, Cheng Chunhui, Yun Fan, Liu Xia, Tang Pingwah, Wu Xinying, Yang Ming and Yuan Qipeng, Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells, Medicinal Chemistry 2016; 12 (8) . https://dx.doi.org/10.2174/1573406412666160404125551
DOI https://dx.doi.org/10.2174/1573406412666160404125551 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets Herpesvirus Saimiri-Based Gene Delivery Vectors
Current Gene Therapy Liver Cancer Stem Cells as an Important Target in Liver Cancer Therapies
Anti-Cancer Agents in Medicinal Chemistry T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) The Use of Herbal Medicine in Cancer-related Anorexia/ Cachexia Treatment Around the World
Current Pharmaceutical Design Gallium Phthalocyanine Photosensitizers: Carboxylation Enhances the Cellular Uptake and Improves the Photodynamic Therapy of Cancers
Anti-Cancer Agents in Medicinal Chemistry Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil
Current Cancer Drug Targets Fasciola Hepatica Extract Induces Cell Death of Mammalian Cells
Anti-Infective Agents A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets The Delivery of Biologically Active (Therapeutic) Peptides and Proteins into Cells
Current Medicinal Chemistry Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Antimicrobial Activity of Phenolics and Glucosinolate Hydrolysis Products and their Synergy with Streptomycin against Pathogenic Bacteria
Medicinal Chemistry Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design A Solvent-free Method for Synthesis of Dihydroangelicins using Microwaves
Current Green Chemistry Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors
Current Drug Targets